Eugene, ORNCT07566156Now EnrollingIRB Ready

Urothelial Cancer Clinical Trial in Eugene, OR

Access cutting-edge urothelial cancer treatment through this clinical trial at a research site in Eugene. Study-provided care at no cost to qualified participants.

Sponsored by Astellas Pharma Global Development, Inc.

Quick Self-Assessment

See if you qualify for this Eugene location

Preparing your pre-screening questions…

Expert Care in Eugene

Access urothelial cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related urothelial cancer treatment provided free

Apply for This Eugene Location

Check if you qualify for this urothelial cancer clinical trial in Eugene, OR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Eugene

    Convenient for OR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Eugene site if eligible
  4. 4Begin participation

About This Urothelial Cancer Study in Eugene

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.

Sponsor: Astellas Pharma Global Development, Inc.

Who Can Participate

Inclusion Criteria

Has histologically confirmed initial diagnosis of muscle-invasive bladder cancer (MIBC) with predominant urothelial histology staged cT2-T4aN0M0
Tissue comprising muscle-invasive urothelial cancer must be submitted for clinical staging at baseline
Eligible for and agree to receive chemoradiotherapy and one of the protocol-specified radiosensitizing chemotherapy regimens
Fit for systemic therapy and elect bladder preservation, including participants who are ineligible for or have elected not to undergo cystectomy
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

Exclusion Criteria

Advanced or metastatic disease (N+, M1), non-urothelial carcinoma, diffuse or multifocal CIS, urothelial carcinoma or histological variant at any site outside the urinary bladder within previous 24 months prior to randomization except Ta/T1/CIS of the upper urinary tract including renal pelvis and ureter if the participant had undergone complete nephrectomy
Has received any prior systemic treatment, chemoradiation, and/or radiation for MIBC or NMIBC
Prior pelvic radiation for any reason
Inadequate bladder function
Other active malignancies within 3 years prior to randomization
Previously treated with enfortumab vedotin or other MMAE-based antibody-drug conjugates (ADCs)
Previously treated with a PD(L)-1 inhibitor, defined as a PD-1 inhibitor or PD-L1 inhibitor
Uncontrolled diabetes
Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of randomization. Routine antimicrobial prophylaxis is permitted
Known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection
Received major surgery (defined as requiring general anesthesia and \>24 hour inpatient hospitalization) within 4 weeks prior to randomization
Known severe (≥ Grade 3) hypersensitivity to any enfortumab vedotin excipient contained in the drug formulation of enfortumab vedotin
Known genetic disorders associated with radiosensitivity (eg, ataxia telangiectasia, Nijmegen breakage syndrome, Fanconi syndrome)
Active keratitis or corneal ulcerations
History of autoimmune disease that has required systemic treatment in the past 2 years
History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
Prior allogeneic stem cell or solid organ transplant
Received a live attenuated vaccine within 30 days prior to randomization

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Eugene?

Yes, this clinical trial (NCT07566156) has an active research site in Eugene, OR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Urothelial Cancer Treatment Options in Eugene, OR

If you're searching for urothelial cancer treatment options in Eugene, OR, this clinical trial (NCT07566156) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Eugene research site is actively enrolling participants for this clinical trial. You'll receive care from experienced urothelial cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all urothelial cancer clinical trials near you to find additional studies recruiting in your area.

More Bladder Cancer Trials in Eugene, OR

See all bladder cancer clinical trials recruiting in Eugene — not just this study.

Browse Bladder Cancer Trials in Eugene →

Browse More Trials by Condition

Bladder Cancer TrialsAll Conditions →

Ready to Join in Eugene?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Eugene, OR